Low Dose of Zoledronic Acid Increases Bone Density

In osteoporosis patients low dose of zolendronic acid than the standard dose decreases bone resorption and increases bone density.

In osteoporosis patients for the prevention of bone fractures, a low dose of zolendronic acid than the standard dose decreases bone resorption and increases bone density. The minimal dosage may be effective in reducing the risk of osteoporosis fractures, finds study.

"Our research suggests that one fifth or one half of the recommended dose might be sufficient to decrease fracture risk," said Andrew Grey, MD, principal investigator of the study and an associate professor of medicine at the University of Auckland in Auckland, New Zealand. "If that is so, it would reduce the health care costs of treating osteoporosis, a common condition, and may reduce the likelihood of side effects of the medication."

Osteoporosis-Causes-Symptoms-Diagnosis-Treatment-FAQs
Osteoporosis is a bone disease that leads to an increased risk of fractures. The bone mass is reduced and the bones are porous, thereby resulting in weakness of the skeletal system of the body.

Currently the manufacturers of zoledronic acid, also called zoledronate, recommend a once-yearly intravenous infusion of 5 milligrams (mg) for prevention of fractures in people with osteoporosis. Women with mild bone loss, or osteopenia, who take the drug to prevent osteoporosis receive a 5-mg dose every other year.

The investigators randomly allocated 180 postmenopausal women with osteopenia to receive a single treatment with either placebo (an inactive substance) or 1 mg, 2.5 mg or 5 mg of zoledronate. None of the women had previously received treatment with zoledronate or any other bisphosphonate medication, according to Grey. The women had tests of their bone mineral density at the lumbar spine (lower back) and the hip before treatment and during one year after treatment.

One year after treatment, bone density was significantly increased in each of the zoledronate groups, compared with the placebo group. The percentage improvement in spine bone density was similar for each zoledronate group, according to the authors: 3.5 percent for the 1 mg dose, 4 percent for the 2.5 mg dose and 3.6 percent for the standard 5.0 mg dose.

Zoledronic Acid

This medication is a bisphosphonate, primarily used for prevention and treatment of osteoporosis in men and postmenopausal women. It is also used for Paget's disease and osteoporosis caused by steroid treatment. It reduces the amount of calcium released from the bones into the blood.

Additionally, blood markers of bone resorption, or bone breakdown, were decreased in the zoledronate groups, compared with the placebo group.

"These results show clearly beneficial effects on bone density and metabolism from lower doses of zoledronate, administered annually," Grey said. "Clinical trials should be undertaken to determine the ability of low doses of zoledronate to prevent fractures."

Quiz on Osteoporosis
Osteoporosis is a debilitating condition that affects all the bones. However, the bones of the hip, wrists and spine are most affected. Learn more about the debilitating disease of Osteoporosis by taking this quiz.

Source-Eurekalert

Bone Density in Healthy Children Not Increased by Vitamin D Supplements
A new Cochrane Systematic Review says that giving vitamin D supplements to healthy children with normal vitamin D levels does not improve bone density at the hip